Regeneron Pharmaceuticals has announced a monumental research collaboration with Parabilis Medicines, a deal valued at an impressive $2.32 billion. This…
Read More
EU Strikes Landmark Deal on Critical Medicines Act to Fortify Pharmaceutical Sector and Ensure Patient Supply
The European Union (EU) has achieved a significant legislative milestone with the provisional agreement on the Critical Medicines Act (CMA),…
Read More
Everest Medicines Acquires Hasten Biopharmaceuticals for $250 Million to Bolster Asia Pacific Chronic Disease Portfolio and Commercial Reach
Everest Medicines, a leading biopharmaceutical company focused on developing and commercializing innovative medicines for chronic diseases, has announced a significant…
Read More
Canada Invests C$79 Million in Aspect Biosystems to Accelerate Development of Bioengineered Cellular Medicines for Endocrine and Metabolic Diseases
Vancouver, BC – Aspect Biosystems, a pioneering company in the field of bioengineered cellular medicines, has received a significant C$79…
Read More
Gilead Sciences to Acquire Ouro Medicines for $2.2 Billion, Ushering in New Era of T-Cell Engagers in Autoimmune Diseases
Gilead Sciences is poised to make a significant entry into the burgeoning field of T-cell engagers (TCEs) with its $2.2…
Read MoreYOU MAY HAVE MISSED
